Your browser doesn't support javascript.
loading
Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab.
Sánchez-Montalvá, Adrián; Sellarés-Nadal, Júlia; Espinosa-Pereiro, Juan; Fernández-Hidalgo, Nuria; Pérez-Hoyos, Santiago; Salvador, Fernando; Durà, Xavier; Miarons, Marta; Antón, Andrés; Eremiev-Eremiev, Simeón; Sempere-González, Abiu; Monforte-Pallarés, Arnau; Bosch-Nicolau, Pau; Augustin, Salvador; Sampol, Júlia; Guillén-Del-Castillo, Alfredo; Almirante, Benito.
Afiliação
  • Sánchez-Montalvá A; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; International Health Program of the Catalan Institut of Health (PROSICS), Barcelona, Spain; Tropical Medicine Spanish Research Network (RICET), Madrid, Spain. Electronic address: a
  • Sellarés-Nadal J; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Espinosa-Pereiro J; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; International Health Program of the Catalan Institut of Health (PROSICS), Barcelona, Spain.
  • Fernández-Hidalgo N; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Infectous Diseases Spanish Research Network (REIPI), Madrid, Spain.
  • Pérez-Hoyos S; Statistic Unit, Vall d'Hebron Institute of Research, Barcelona, Spain.
  • Salvador F; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; International Health Program of the Catalan Institut of Health (PROSICS), Barcelona, Spain; Tropical Medicine Spanish Research Network (RICET), Madrid, Spain.
  • Durà X; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Miarons M; Pharmacy Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Antón A; Microbiology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Infectous Diseases Spanish Research Network (REIPI), Madrid, Spain.
  • Eremiev-Eremiev S; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sempere-González A; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Monforte-Pallarés A; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bosch-Nicolau P; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Augustin S; Hepatology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sampol J; Pneumology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Guillén-Del-Castillo A; Internal Medicine Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Almirante B; Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Infectous Diseases Spanish Research Network (REIPI), Madrid, Spain.
Med Clin (Barc) ; 158(11): 509-518, 2022 06 10.
Article em En, Es | MEDLINE | ID: mdl-34544604
BACKGROUND: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. METHODS: We report the preliminary results from the Vall d'Hebron cohort study at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed SARS-CoV-2 infection and who were treated with tocilizumab until March 25th. RESULTS: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5-11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3-8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8-5.8) if tocilizumab was administered after the onset of ARDS. CONCLUSION: Early administration of tocilizumab in patients needing oxygen supplementation may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data regarding the precise timing in of initiation of the treatment with tocilizumab.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome do Desconforto Respiratório / Insuficiência Respiratória / Tratamento Farmacológico da COVID-19 Idioma: En / Es Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome do Desconforto Respiratório / Insuficiência Respiratória / Tratamento Farmacológico da COVID-19 Idioma: En / Es Ano de publicação: 2022 Tipo de documento: Article